IRB #

STUDY00016255

Title

INCB 54828-202: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Principal Investigator

Gina Vaccaro

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of the study drug, INCB054828, in patients with advanced or surgically unresectable Cholangiocarcinoma.

Medical Condition(s)

Advanced/Metastatic Cholangiocarcinoma
Surgically Unresectable Cholangiocarcinoma

Eligibility Criteria

≥ 18 years of age
Cholangiocarcinoma
Previously treated with at least one prior line of systemic therapy

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will receive the study drug until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.

Minors Included

No

Contact

OHSU Knight Cancer Institute Information line 503-494-1080
trials@ohsu.edu

Sponsor

Incyte Corporation

Recruitment End

12/31/2030

Compensation Provided

No


Go Back